CORRIGENDUM to ‘Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis’

Abstract

Konstantina Drellia, Lili Kokoti, Christina I Deligianni, et al. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. Cephalalgia 2021; 41(7): 851–864. DOI: 10.1177/0333102421989601

On page 857, Table 3, has been corrected and reproduced here; bold entries have been updated.

Table 3.

Efficacy, safety and benefit/risk outcomes in trials with anti-CGRP mAbs in the prophylaxis of chronic migraine.

Values	HALO-CM (28)		REGAIN (26)		PROMISE-2 (27)
Values	FREMA 225 mg monthly	FREMA 675 mg high dose	GALCA 120 mg	GALCA 240 mg	EPTI 100 mg	EPTI 300 mg
NNTB_50% (95% CI)	5(3.4–6.1)	6(3.8–7.5)	9(5.6–15.8)	9(5.6–16)	6(3.9–9)	5(3.4–6.7)
NNTH_AE (95% CI)	14(7.2 to ∞ to NNTB 172.1*)	16(7.6 to ∞ to NNTB 457.4*)	13(6.5 to ∞ to NNTB 96.5*)	15(7.2 tο ∞ to NNTB 249.5*)	31(9.5 to ∞ to NNTB 24.5*)	19 (7.9 to ∞ to NNTB 49*)
LHH_(AE/50%)	2.8	2.7	1.4	1.7	5.1	3.8
NNTH_SAE (95% CI)	357(50.2 to ∞ to NNTB 69.9*)	125(42.4 to ∞ to NNTB 132.7*)	286 (68 to ∞ to NNTB 130.1*)	95(39.5 to ∞ to NNTB 240.1*)	4,344(74.2 to ∞ to NNTB 76.8*)	310 (56.5 to ∞ toNNTB 89*)
LHH_(SAE-50%)	71.4	20.8	31.8	10.6	724	62
NNTH_(D-AE) (95% CI)	350(43.8 to ∞ to NNTB 58.6*)	125(37.8 to ∞ to NNTB 94.2*)	25,854(67.2 to ∞ to NNTB 67.5*)	283(56.9 to ∞ to NNTB 95.2*)	338 (66.4 to ∞ to NNTB 109.4*)	58(28.9 to ∞ to NNTB 4,099.6*)
LHH_(D-AE/50%)	70	20.8	2,872.7	31.4	56.3	11.6

Note: NNTB50%: number needed to treat (NNT) values for 50% responder rate in phase-3 and trials for migraine prophylaxis (only for erenumab, the study was phase 2b).

ERE: erenumab; FREMA: fremanezumab; GALCA: galcanezumab; EPTI: eptinezumab; PLB: placebo; 95% CI: confidence intervals; LHHD-AE/50%: the likelihood of achieving the 50% responder outcome vs. experiencing any adverse event leading to treatment discontinuation; NNTHAE: number of patients that need to be treated for a patient to experience an adverse event; NNTHSAE: number of patients that need to be treated for a patient to experience a serious adverse event; NNTHD-AE: number of patients that need to be treated for a patient to experience an adverse event that will lead to treatment discontinuation; NNTHD-AE: number of patients that need to be treated for a patient to experience an adverse event that led to treatment discontinuation; in some cases the harmful effect of the treatment leading to an AE was not significantly different from placebo at the p 0.05 level and resulted in the 95% CIs of the NNTH to include infinity (1).

*No significant difference between active treatment and placebo.

Text in the Results section on page 856, right-hand column, second line should read (correction in bold):

In particular, the LHH_D-AE/50% of fremanezumab, galcanezumab and eptinezumab varied from 20.8 to 70, 31.4 to 2872.7 and 11.6 to 56.3, respectively.